CHROMONAR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H27NO5
Molecular Weight	361.4321
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)COC1=CC2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2

InChI

InChIKey=KLOIYEQEVSIOOO-UHFFFAOYSA-N

InChI=1S/C20H27NO5/c1-5-21(6-2)11-10-17-14(4)16-9-8-15(12-18(16)26-20(17)23)25-13-19(22)24-7-3/h8-9,12H,5-7,10-11,13H2,1-4H3

HIDE SMILES / InChI

Description
Sources: http://lekarstwo.ru/en/preparati/carbocromenum.html
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800000219

Chromonar is a coronary vasodilator agent, it dilates coronary vessels and increases coronary blood flow volume rate, contributes to the development of collateral circulation (with prolonged use), improves metabolic processes in myocardium. The mechanism of action of a role played by its inhibitory effect on phosphodiesterase, accompanied by accumulation in the cells of cyclic 3 ', 5'-adenosine monophosphate. Due to the relatively low therapeutic efficacy Chromonar use is limited, mainly in the early stages of coronary heart disease with angina pectoris in the absence of long-standing and long strokes, when there is no expressed stenotic process.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Platelet Aggregation (Plug Formation) 5 Target ID: WP1884 Sources: http://www.ncbi.nlm.nih.gov/pubmed/947200	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Coronary artery disease 48 Sources: http://www.ncbi.nlm.nih.gov/pubmed/756818	Primary		Approved 8429	Intensain Approved Use Indications for use: Angina without expressed stenotic process protracted and prolonged attacks, postinfarction period.

PubMed

Title	Date	PubMed
Cloricromene in endotoxemia: role of NF-kappaB.	2004 Aug	15322736

Patents

Sample Use Guides

In Vivo Use Guide

Inside after food: 0,075 - 0,15 g (1 - 2 tablets) 3 times a day. In more severe cases, to begin receiving 0.15 g 4 times a day, and after improving the dose is reduced to 0.075 g of 3 - 4 times daily. It is noted that the effect of the drug increases (to 10 - 30th day) and lasts a long time. Take in a few weeks or months (up to 6 months).

Route of Administration: Oral

In Vitro Use Guide

In bovine heart mitochondria ho/h-1 ratios in repeated scans increased in presence of carbocromen (20--40 umol/l)

Name

Type

Language

CHROMONAR

Common Name

English

ACETIC ACID, ((3-(2-(DIETHYLAMINO)ETHYL)-4-METHYL-2-OXO-2H-1-BENZOPYRAN-7-YL)OXY)-, ETHYL ESTER

Common Name

English

((3-(2-(DIETHYLAMINO)ETHYL)-4-METHYL-2-OXO-2H-1-BENZOPYRAN-7-YL)OXY)ACETIC ACID ETHYL ESTER

Systematic Name

English

AG-3 FREE BASE

Code

English

carbocromen [INN]

Common Name

English

Carbocromen [WHO-DD]

Common Name

English

A-27053 FREE BASE

Code

English

CARBOCROMEN

Official Name

English

NSC-110430 FREE BASE

Code

English

CHROMONAR [MI]

Common Name

English

Classification Tree Code System Code

WHO-ATC

C01DX05